Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Revance Therapeutics, Inc.

< Previous 1 2 Next >
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Participate in the Needham 22nd Annual Healthcare Conference
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Participate in the 43rd Annual Cowen Healthcare Conference
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Participate in the Stifel 2022 Healthcare Conference
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Announces Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessment
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Release Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Appoints David A. Hollander, M.D., M.B.A. as Chief Medical Officer
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Participate in the Guggenheim Nantucket Therapeutics Conference
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY™ (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congress of Parkinson and Movement Disorder Society (MDS)
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Announces Proposed Public Offering of Common Stock
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.